HYDRATE CRYSTAL FORM OF LAZERTINIB METHANESULFONATE, PREPARATION METHOD THEREFOR AND USE THEREOF

This application relates to the field of chemistry of drugs. It relates to a lazertinib monomethanesulfonate hydrate crystal form, its preparation method thereof and uses. The crystal form of lazertinib monomethanesulfonate hydrate provided in this application has at least one of the following advan...

Full description

Saved in:
Bibliographic Details
Main Authors PENG, Chenyue, SHENG, Xiaohong, SHENG, Xiaoxia
Format Patent
LanguageEnglish
French
German
Published 10.04.2024
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This application relates to the field of chemistry of drugs. It relates to a lazertinib monomethanesulfonate hydrate crystal form, its preparation method thereof and uses. The crystal form of lazertinib monomethanesulfonate hydrate provided in this application has at least one of the following advantageous properties: good stability, high solubility, good dissolution, low hygroscopicity, uniform particle size distribution, favorable morphology, good flowability, and high crystallinity. These characteristics contribute to stable storage, preventing degradation, increased impurities, changes in appearance, and crystallization during development and storage. The preparation method is simple and reliable, offering significant development value.
Bibliography:Application Number: EP20220815303